In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $105.00.
Michael Ulz has given his Buy rating due to a combination of factors related to Viking Therapeutics’ promising developments in the obesity treatment market. The recent decision by Pfizer to halt the development of its oral GLP-1 drug, danuglipron, due to safety concerns, provides a positive outlook for Viking Therapeutics’ own oral GLP-1/GIP formulation, VK2735.
Viking’s VK2735 has shown encouraging results in early trials, demonstrating both activity and tolerability in a short-term study. The ongoing Phase 2 VENTURE-Oral study, which has completed enrollment, is expected to deliver data in the second half of 2025. The potential for VK2735 to serve as a maintenance option in the competitive obesity treatment landscape, coupled with Pfizer’s program discontinuation, strengthens the case for a Buy rating.
According to TipRanks, Ulz is an analyst with an average return of -9.8% and a 33.68% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Viking Therapeutics.